anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In anesthesia, the synergistic interaction between hypnotics and opioids is applied daily to give adequate anesthesia and analgesia at significantly lower doses compared with the ones needed if only one drug was given to reach the same effect. A lot of research has been done to quantify these interactions with a focus on the desired effects (Tolerance of laryngoscopy, tolerance of shake and shout etc...), but the simultaneous interaction on the unwanted side effects is less well described. The response surface model of Bouillon et al. and other models predict combinations of propofol and remifentanil effect-site concentrations that lead to an equipotent desired effect. Due to the availability of the models, the anesthesiologists now could use the knowledge on interactions to target specific effects more accurately, using predefined equipotent combinations of drugs: for instance, a desirable 90% probability of tolerance of laryngoscopy (TOL90) in the population can be reached through either a high propofol/low remifentanil combination, but equally well through a low propofol-high remifentanil combination.

However, at this time it is not known whether some of the combinations of propofol and remifentanil have a favorable hemodynamic stability compared to other equipotent combinations. The researcher in this study want to determine whether equipotent combinations of remifentanil and propofol (all deliberately selected to evoke 90% probability of "tolerance to laryngoscopy"), result in different effects on the undesired side effects of anesthetics, such as hemodynamic instability (hypotension, changes in heart rate or cardiac output), decreases in cerebral or tissue oxygenation (both measured with near infrared spectroscopy).
BACKGROUND: With increasing trend of internet use in all age groups, whether internet use can prevent frailty in middle-aged and older adults remains unclear.
METHODS: Five cohorts, including Health and Retirement Study (HRS), China Health and Retirement Longitudinal Study (CHARLS), the Survey of Health, Ageing and Retirement in Europe (SHARE), English Longitudinal Study of Aging (ELSA), and Mexican Health and Aging Study (MHAS), were used in this study. Internet use, social isolation, and frailty status was assessed using similar questions. The Generalized estimating equations models, random effects meta-analysis, COX regression, and mediation analysis were utilized.
RESULTS: In the multicohort study, a total of 155,695 participants were included in main analysis. The proportion of internet use was varied across countries, ranging from 5.56% in China (CHARLS) to 83.46% in Denmark (SHARE). According to the generalized estimating equations models and meta-analysis, internet use was inversely associated with frailty, with the pooled ORs (95%CIs) of 0.72 (0.67,0.79). The COX regression also showed that participants with internet use had a lower risk of frailty incidence. Additionally, the association was partially mediated by social isolation and slightly pronounced in participants aged 65 and over, male, not working for payment, not married or partnered, not smoking, drinking, and not co-residence with children.
CONCLUSIONS: Our findings highlight the important role of internet use in preventing frailty and recommend more engagements in social communication and activities to avoid social isolation among middle-aged and older adults.
Clinical records of patients over 18 years of age with a clinical diagnosis of organic vascular ED, of more than three months and with an erection hardness score (EHS)(17) of three or less, treated between April 2014 and February 2015 in the Boston Medical Group male sexual health clinics of twelve cities in Spain (Madrid, Barcelona, Valencia, Seville, Coruña, Bilbao, Malaga, Zaragoza, Murcia, Alicante, Cordoba and Jerez) and four in Mexico (Altavista, Reforma, Monterrey and Naucalpan), were reviewed. The researchers excluded patients with ED caused by side effects from drugs or spinal cord injury; situational ED (obvious psychological origin); lesions, loss of skin or penile implant; and patients who did not adequately complete the LI-ESWT (Low-intensity extracorporeal shock wave therapy).

After the initial assessment and diagnosis consultation, each patient received a treatment of 5 sessions (1 session per week) of 20 minutes of LI-ESWT, carried out with the DUOLITH SD1 (Storz Tägerwilen, Switzerland). They received 3,000 impulses per session at 0.1 mJ/mm2, divided over six sites, four on the penis and two on the crura. All sessions were outpatient visits and no anaesthetic was used. The EHS for all patients was measured at three stages: before the first session, at the end of the last session (5 weeks after the first session) and one month after the last session. When patients were receiving concomitant drug treatment for their dysfunction, they were asked to indicate their perception free of the effect thereof. All the clinical information was recorded by qualified physicians on a standardised form using centralised software on a secure server.
BACKGROUND: Excess muscle fat is observed in obesity and associated with greater burden of cardiovascular risk factors and higher risk of mortality. Liraglutide reduces total body weight and visceral fat but its effect on muscle fat and adverse muscle composition is unknown.
METHODS: This is a pre-specified secondary analysis of a randomized, double-blind, placebo-controlled trial that examined the effects of liraglutide plus a lifestyle intervention on visceral adipose tissue and ectopic fat among adults without diabetes with body mass index ≥30 kg/m2 or ≥27 kg/m2 and metabolic syndrome. Participants were randomly assigned to a once-daily subcutaneous injection of liraglutide (target dose 3.0 mg) or matching placebo for 40 weeks. Body fat distribution and muscle composition was assessed by magnetic resonance imaging at baseline and 40-week follow-up. Muscle composition was described by the combination of thigh muscle fat and muscle volume. Treatment difference (95% confidence intervals [CI]) was calculated by least-square means adjusted for baseline thigh muscle fat. The association between changes in thigh muscle fat and changes in body weight were assessed using Spearman correlation coefficients. The effect of liraglutide versus placebo on adverse muscle composition, denoted by high thigh muscle fat and low thigh muscle volume, was explored.
RESULTS: Among the 128 participants with follow-up imaging (92.2% women, 36.7% Black), median muscle fat at baseline was 7.8%. The mean percent change in thigh muscle fat over median follow-up of 36 weeks was -2.87% among participants randomized to liraglutide (n = 73) and 0.05% in the placebo group (absolute change: -0.23% vs. 0.01%). The estimated treatment difference adjusted for baseline thigh muscle fat was -0.24% (95% CI, -0.41 to -0.06, P-value 0.009). Longitudinal change in thigh muscle fat was significantly associated with change in body weight in the placebo group but not the liraglutide group. The proportion of participants with adverse muscle composition decreased from 11.0% to 8.2% over follow-up with liraglutide, but there was no change with placebo.
CONCLUSIONS: In a cohort of predominantly women with overweight or obesity in the absence of diabetes, once-daily subcutaneous liraglutide was associated with a reduction in thigh muscle fat and adverse muscle composition compared with placebo. The contribution of muscle fat improvement to the cardiometabolic benefits of liraglutide requires further study.
The present invention describes a technical method which can be used to load prefabricated contact lenses or other ophthalmological polymers sufficiently with drugs within the range from 1 to 50% (by weight) without altering the fundamental structural properties. This method results in continuously controlled release systems with reproducible properties for achieving a physical and medical effect. With a sufficiently high loading (> 1% by weight), therapeutically effective release rates are achieved in the absence of toxic effects and minimisation of side effects on local use of, for example, mitomycin from a collagen carrier for intraocular fibroblast inhibition in cases of drainage of aqueous humour. The invention furthermore relates to the control of the kinetics of release within a wide range from 0 order release to t<2> proportionality by means of different evaporation or extraction techniques. The invention furthermore contains the possibility of increasing or reducing the duration of release in relation to the amount released. On practical use of the invention, every drug able to diffuse through the polymeric matrix and producing a local corneal or conjunctival therapeutic effect, and the esters, ethers, amides or salts of these drugs, are suitable. The incorporated drugs... Original abstract incomplete.
The investigators will enroll a cohort of 8-10 HIV-1 seronegative, HSV-2 seropositive persons with recurrent genital HSV-2 lesions in an area amenable to genital biopsy. Participants will enroll when they have a genital lesion. They will undergo a lesion biopsy and a non-lesion biopsy. They will start suppressive valacyclovir 500 mg po daily for 4 weeks. Three days after completion of the 4 week valacyclovir course, participants will initiate vaccination with HSV529 on a 0, 1, and 6 month dose schedule. At each vaccination visits and at the 10 days post vaccination visits, genital biopsies will be performed. Genital biopsies will be performed at the site of genital lesion and at a non-lesional genital site. PBMC will also be drawn. Two days after the second vaccination, an optional biopsy will be offered. Overall, a minimum of 14 genital biopsies will be performed for each participant: 7 at the genital lesion site, and 7 at the genital non-lesion site. Four control biopsies from the upper arm will also be performed. For participants who undergo the optional biopsy two days after Dose 2, two additional genital biopsies will be performed. Participants will also collect daily genital swabs for HSV PCR for 30 days after each vaccination.
The control group will consist of healthy individuals. 21 healty volunteers will be included in the study.
FIELD: medicine, organic chemistry, biochemistry, pharmacy. SUBSTANCE: invention relates to agent for inhibition of activity of endothelin-converting enzymes and representing compound of the formula (I)  . Invention relates also to method for its preparing and pharmaceutical compositions containing compound of the formula (I) as an active component. Compounds of the formula (I) show inhibitory activity with respect to endothelin-converting enzymes. EFFECT: valuable medicinal and biochemical properties of compounds. 8 cl, 1 tbl, 11 ex
Extracts of hypericum perforatum (St. John's wort) have become increasingly popular for the treatment of mood disorders. Hypericum extracts have been approved in Germany for the treatment of mild to moderate depression and are now available in standardized preparations. In the United States, hypericum extracts are frequently purchased as over the counter preparations. Inhibition of the serotonin transporter, similar to clinically used selective serotonin reuptake inhibitors (SSRIs), has been suggested as a possible mechanism of action for the antidepressant properties of hypericum extracts. We propose to study the effects of hypericum extracts on mood states in normal volunteers who are concurrently volunteering under NIMH protocol 98-M-0094 for SPECT imaging of serotonin and dopamine transporter availability with \[I-123\] Beta-CIT. A placebo-controlled, double-blind, within-subject design will be employed with two two-week periods of drug/placebo administration, clinical assessment and SPECT imaging separated by eleven weeks. We plan to test three hypotheses: 1) that hypericum alters mood state, 2) that hypericum reduces serotonin transporter availability, and 3) that these actions are quantitatively associated with one another.
The present invention pertains to a method that effectively helps reducing body weight and food intake. The method includes self-administering and depositing into the stomach, via a capsule or similar carrier, various objects of various materials including an automatic self-inflating hygienic balloon or more, of various sizes, made of edible or non-harmful materials, by swallowing a capsule containing the balloon or the object, that self inflates to different pre-determined sizes, thus occupying a volume of stomach, hence reducing food intake and feeling of fullness. The method does not require any medical intervention, or inflation pumps and tubes . . . The capsule or the carrier can be self-employed in several sizes and made from Natural or non-harmful synthetics, wherein the inflation can be accomplished by utilizing natural materials, for both the balloon and its contents, preferably by Baking Soda and Vinegar, or Yeast based products.
This is a double-blind, placebo-controlled, randomized, prospective, phase IV trial with parallel design. 126 of new cardiac transplant recipients are planned to be enrolled in two sites: 1) Transplant Centre at Institute for Clinical and Experimental Medicine, Prague, Czech Republic, and 2) St Anne's University Hospital (FNUSA) - Centre of Cardiovascular and Transplant Surgery (CKTCH) in Brno, Czech Republic. Screening data will be reviewed to determine subject eligibility. Subjects who meet all inclusion criteria and none of the exclusion criteria will be entered into the study. Screening period could last up to four weeks. Subjects will be randomized 1:1 to receive either alirocumab 150 mg every 2 weeks or placebo between month 1 and month 12 after transplantation (study treatment will start after the first surveillance cardiac catheterization approximately one month after heart transplantation and it will be completed after the second surveillance cardiac catheterization approximately 12 months after heart transplantation). Furthermore, all subjects will be on a background statin treatment with atorvastatin 10 mg daily. After Screening and Baseline visit, 5 visits are planned during the treatment period (4, 8, 20, 34 and 48 weeks after baseline) and follow-up visit is planned 60 weeks after baseline. Maximal expected duration of subject participation will be 15 months.
Provided is a technology for managing clinical state using an ophthalmological examination device installed at the home or the like of a patient. This patient management system contains: a plurality of ophthalmological examination devices allocated to a plurality of patients; and a plurality of computers installed at a plurality of medical institutions. Each ophthalmological examination device and each computer can communicate with a server via a communication line. The server manages patient accounts and the accounts of each medical institution. Examination data acquired by the ophthalmological examination devices are stored in the patient accounts. The server transmits information stored in the patient accounts to the computer installed at the medical institution allocated ahead of time to each patient.
An antibiotic, (l) - #Y - 1 - p - nitrophenyl - 2 - dichloroacetamidopropane-1 : 3-diol, is obtained by cultivating Streptomyces venezuelae in contact with a nutrient medium under aerobic conditions (i.e. on the surface of the medium, e.g. for 10-15 days at 25 DEG  C., or in the submerged condition with aeration and agitation, e.g. for 2-7 days at 25 DEG  C.).  The nutrient medium is preferably an aqueous medium containing an assimilable carbon source (a polyhydric alcohol or a mono-, di- or poly-saccharide, e.g. glucose, fructose, sucrose, inulin, dextrins, starches and especially sugar alcohols such as sorbitol and particularly glycerol) and a proteinaceous material (unmodified protein or protein degradation products such as proteoses, peptones, polypeptides, peptides and amino acids).  The carbon source or the proteinaceous material or both together may also be provided by various complex products, e.g. liquefied or modified starches, molasses, corn syrup; acid or enzyme hydrolysed casein, distillers' grain slops, distillers' solubles, soybean meal, acid hydrolysed corn or wheat gluten, peptone, brewers' yeast, offals, synthetic mixtures of amino acids; whey concentrates, grain p  mashes, corn and wheat steep liquor.  The antibiotic may be isolated from the culture medium by the following series of steps: (a) clarifying the liquid below about pH 10; (b) extracting the solution with an organic solvent having a solvent-water distribution coefficient for the antibiotic above about 9 (e.g. cyclohexanone, butanol, ethyl acetate or methyl isobutyl ketone); (c) removing the solvent from the extract; (d) extracting the residue with an organic solvent having a distribution coefficient between about 1 and 9 (e.g. nitrobenzene, nitromethane, diethyl ether or ethylene dichloride); (e) washing the extract with dilute mineral acid and water (and preferably also with dilute alkali); (f) adding water to the organic solvent extract; (g) evaporating the organic solvent from the mixture; (h) extracting the aqueous solution with an organic fat solvent in which the antibiotic is substantially insoluble (e.g. benzene or petroleum ether); (i) evaporating the aqueous solution to the point of crystallization. Alternatively, steps (b) and (c) may be omitted, the clarified solution being directly extracted with the type of solvent used in (d).  Again, when the solvent used in (d) is a lower dialkyl ether, the washing step (e) may be replaced by passage of the solution over an aluminium oxide type adsorption column.  A further alternative consists in adsorbing the antibiotic from the clarified culture liquid on to activated charcoal, eluting it with ether or 80 per cent acetone, adding water, distilling of the organic solvent, removing any gummy material which separates and concentrating the aqueous solution to the point of crystallization. Examples illustrate various features of the invention.
The study was planned as a randomized controlled trial, and children aged 7-17 who were diagnosed with "Special Learning Disability" in a special education center in Kocaeli-Darica were included as a sample. Children were divided into experimental and control groups by randomization. In addition to the individual training program they received from the special training center, the experimental group was given goal-oriented balance and coordination exercises for 8 weeks, 2 days a week for 40 minutes. The control group continued only the individual training program. All participants and their parents were informed about the study, and an informed consent form was obtained from the participants and their parents. In order to collect data from the participants; "Leisure Time Activity Questionnaire for Children" to determine physical activity levels, "Quality of Life Assessment Questionnaire for Children" to determine their quality of life, "Bruininks-Oseretsky Motor Proficiency Test 2 short form" to evaluate motor skills, "Burdon Attention Test" to measure attention level used. These tests and forms were repeated before starting the study and at the end of the study. Pre- and post-intervention data were statistically analyzed and compared.
A standard saline solution in a bottle covered with opaque white paper and refrigerated at 4°C was prepared. Saline solution was sprayed for the same duration and at the same distance from the injured area as well like coolant spray application. The first spray application was performed after the initial assessment, and the second spray application was performed at the end of the 30th minute (immediately after the pain level/score measurement). All patients were given intravenous (IV) dexketoprofen (50 mg in 50 ml standard saline solution) in 5 minutes simultaneously with the first spray application. The physicians applied the designated treatment protocol for each treatment group. As a rescue analgesic treatment, patients were scheduled to be given IV fentanyl at a dose of 1 mcg/kg.
Needlescopic instruments, defined as those with a diameter of no more than 3 mm. They result in smaller incisions than conventional 5- to 12-mm instruments, and thus better cosmesis. It may further reduce postoperative pain, hospital stay, and recovery time.

All operations were performed with the lateral transperitoneal approach. A 12-mm port was created near the umbilicus for a 30-degree telescope, and another two(for left lesions) or three (for right lesions) 2-mm working ports (Tyco Healthcare, Norwalk, Connecticut, USA) were created along the ipsilateral subcostal region. Careful dissection was done with the use of a 2-mm hook or scissors electrocoagulator. The adrenal vein of the lesion side was isolated and controlled with a 2-mm mini-bipolar coagulation apparatus (Tyco Healthcare) for a long segment. The vein was then transected closer to the adrenal gland, leaving the coagulated stump at the renal vein or vena cava as long as possible, even when a short right adrenal vein was encountered. Then the adrenal gland with the tumor was dissected from its surrounding tissues after several tiny vessels were transected with the needlescopic instruments mentioned above. The specimen was put into a retrieval bag and removed through the umbilical port.
The SPARK is an evidence based plan designed to improve health-related well-being and to maintain the positive socialization and enjoyment of physical activities or academic achievements.(4) The SPARK discipline is in line with NASPE (National Association of Sport and PE) guidelines. A standard SPARK lesson will be delivered in two parts: a health fitness activity and a skill-fitness activity. In the health fitness activity part, there will be 13 activities that include aerobic dance, running games and jump ropes. In this part, the main focus will be on developing cardiovascular endurance and promotion by modifying the intensity, duration and complexity of the activities. The activities will be mostly aimed to develop abdominal and upper body strength.
Subjects receive weekly infusion of CRLX101 in combination with bi-weekly bevacizumab (10 mg/kg. The starting dose is 12 mg/m\^2 and the next dose level is 15 mg/m\^2. No other dose levels will be explored.
The present invention is directed to a system and method for providing care to a patient, comprising a patient care device having a number of configuration databases stored in a memory in the device. Each configuration database preferably includes protocols, operating limits, rule sets and/or operating features that collectively define an operating environment, or personality, of the device. Selection of a specific configuration database preferably is based at least in part upon patient-specific information obtained from any location in a distributed hospital network. Examples of such patient-specific information include patient age or size, patient medical characteristics, a location of the patient or a location of the care device. In a preferred embodiment, programming a patient care device to deliver a drug to a patient entails activating a configuration database and scanning a machine-readable drug label identifying a particular protocol stored in the activated database. The selected protocol includes default parameters for delivering the drug, and the label optionally includes instructions for deviating from the default protocol.